Nurse Practitioner Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Ashley Christensen

Emergency Medicine Pendleton, OR Nurse Practitioner

NPI 1073082046 CMS profile 6462474

3001 St Anthony Way, Pendleton, OR 97801

Open in the dashboard

General payments

$2,111

34 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ashley Christensen of Pendleton, OR is reported in the CMS Open Payments database as having received $2,111 across 34 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Emergency Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $916 22
2024 General $945 4
2023 General $184 5
2022 General $66 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ashley Christensen
  • Emergency Medicine median
  • Middle half of Emergency Medicine
  • National median

In program year 2025, general payments to Ashley Christensen were reported at $916. Among 10,690 Emergency Medicine profiles paid that year, the median was $57 and the middle half received between $24 and $150.

Show as a table
Year Ashley Christensen Emergency Medicine median Middle half National median
2019 $0 $51 $18–$128 $163
2020 $0 $29 $16–$99 $114
2021 $0 $40 $18–$124 $132
2022 $66 $49 $20–$134 $149
2023 $184 $51 $22–$142 $160
2024 $945 $52 $22–$150 $164
2025 $916 $57 $24–$150 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Inspire Medical Systems, Inc. $1,745 21 payments
  2. Jazz Pharmaceuticals Inc. $117 2 payments
  3. Harmony Biosciences LLC $55 2 payments
  4. Fisher & Paykel Healthcare Inc $42 2 payments
  5. ITI, Inc. $35 2 payments
  6. Lilly USA, LLC $30 1 payment
  7. Sanofi Pasteur Inc. $27 1 payment
  8. Pfizer Inc. $27 1 payment
  9. AbbVie, Inc. $20 1 payment
  10. Indivior Inc. $13 1 payment

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Travel and Lodging $1,177 4 payments
  2. Food and Beverage $834 29 payments
  3. Education $100 1 payment
Products named General payments · program years 2022–2025
  1. INSPIRE $1,745 21 payments
  2. XYREM $100 1 payment
  3. FISHER & PAYKEL HEALTHCARE Sleep $42 2 payments
  4. FISHER & PAYKEL HEALTHCARE Sleep $42 2 payments
  5. FISHER & PAYKEL HEALTHCARE Sleep $42 2 payments
  6. FISHER & PAYKEL HEALTHCARE Sleep $42 2 payments
  7. FISHER & PAYKEL HEALTHCARE Sleep $42 2 payments
  8. CAPLYTA $35 2 payments
  9. WAKIX $31 1 payment
  10. ZEPBOUND $30 1 payment
  11. Other $180 8 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 43 drugs

Part D claims

1,274

Median for Nurse Practitioner: 389

Drug cost

$77,550

Median for Nurse Practitioner: $21,885

Branded share of claims

19.3%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 27 $29,447
Januvia Sitagliptin Phosphate Brand 22 $11,060
Jardiance Empagliflozin Brand 17 $10,832
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 13 $6,247
Dapagliflozin Dapagliflozin Propanediol Brand 11 $4,219
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 16 $1,364
Atorvastatin Calcium Generic 81 $1,323
Albuterol Sulfate Hfa Albuterol Sulfate Brand 29 $1,127
Metoprolol Succinate Generic 59 $953
Gabapentin Generic 105 $928

The 10 drugs with the highest cost, of 43 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Records

34 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Emergency Medicine in Oregon

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record